15962-97-7 Usage
Description
(1-methoxymethoxy-1-methylprop-2-ynyl)benzene is a complex organic chemical compound derived from benzene. It features a methoxy group, a methoxyethoxy group, and a methylpropynyl group attached to its structure. (1-methoxymethoxy-1-methylprop-2-ynyl)benzene serves as a versatile building block in organic synthesis, with its specific properties and applications varying depending on the chemical context and environment.
Uses
Used in Organic Synthesis:
(1-methoxymethoxy-1-methylprop-2-ynyl)benzene is used as a building block in organic synthesis for its ability to contribute to the formation of more complex molecules. Its unique structure allows it to be a valuable component in creating a wide range of chemical products.
Used in Industrial Applications:
(1-methoxymethoxy-1-methylprop-2-ynyl)benzene finds use across various industries due to its potential role in the synthesis of different types of products. Its applications can range from pharmaceuticals to materials science, depending on the specific needs of the industry and the compound's compatibility with other chemicals in the synthesis process.
Additional study and analysis are necessary to fully understand the potential applications and hazards of (1-methoxymethoxy-1-methylprop-2-ynyl)benzene, ensuring its safe and effective use in various chemical and industrial processes.
Check Digit Verification of cas no
The CAS Registry Mumber 15962-97-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,9,6 and 2 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 15962-97:
(7*1)+(6*5)+(5*9)+(4*6)+(3*2)+(2*9)+(1*7)=137
137 % 10 = 7
So 15962-97-7 is a valid CAS Registry Number.
15962-97-7Relevant articles and documents
3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS
-
Paragraph 0219-0221, (2013/09/26)
Compounds of the formula I in which Q, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are PDK1 inhibitors and can be employed for the treatment of tumours.
